Jasper to present data on briquilimab at 2023 Fanconi Anemia symposium

Jasper Therapeutics announced new positive Phase 1b data on briquilimab as a conditioning agent in the treatment of Fanconi Anemia. The data will be featured in a presentation at the 2023 Fanconi Anemia Research Fund Scientific Symposium, taking place on September 28 – October 1, 2023, in Vancouver, Canada. The ongoing investigator initiated Phase 1/2 clinical trial is evaluating a conditioning regimen that includes briquilimab as a potential treatment for FA patients in bone marrow failure. Utilizing briquilimab, the regimen eliminates the need for busulfan chemotherapy or total body irradiation. “The updated results from the Phase 1b study, which will be presented at FARF, are very encouraging,” said Ronald Martell, President, and Chief Executive Officer of Jasper. “All three FA patients who underwent conditioning with briquilimab achieved full blood count recovery. The treatment was tolerated without any complications, leading to remarkable levels of donor chimerism and no briquilimab-related adverse events or toxicities. These outcomes underscore the potential for briquilimab conditioning regimen to redefine the landscape of FA therapy. We look forward to the expansion of the study to Phase 2a by Stanford.”